Showing results (1-10 of 66) with videos related to
Sort By:
Pageof 7
Cancer Research|June 17, 2005
Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activityPhilippe Clézardin, Frank H Ebetino, Pierrick G J FournierNeoplasia (New York, N.Y.)|July 24, 2010
How do bisphosphonates inhibit bone metastasis in vivo?Pierrick G Fournier, Verena Stresing, Frank H Ebetino, et al.BMC Veterinary Research|June 26, 2019
Bisphosphonate use in the horse: what is good and what is not?Alexis Mitchell, Ashlee E Watts, Frank H Ebetino, et al.Biochemical and Biophysical Research Communications|January 12, 2002
Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthaseKeith Thompson, James E Dunford, Frank H Ebetino, et al.Biochemical and Biophysical Research Communications|October 22, 2008
Geranylgeranyl transferase type II inhibition prevents myeloma bone diseaseMichelle A Lawson, Les Coulton, Frank H Ebetino, et al.Chemical Communications (Cambridge, England)|May 10, 2011
A serendipitous phosphonocarboxylate complex of boron: when vessel becomes reagentKatarzyna M Błażewska, Ralf Haiges, Boris A Kashemirov, et al.Bioorganic & Medicinal Chemistry Letters|December 15, 2007
Synthesis and biological activity of novel peptide mimetics as melanocortin receptor agonistsXue-Wei Liu, Jimei Ma, Anny-Odile Colson, et al.Organic Letters|April 12, 2003
Synthesis of 2,4,5-trisubstituted tetrahydropyrans as peptidomimetic scaffolds for melanocortin receptor ligandsAnna Kulesza, Frank H Ebetino, Rajesh K Mishra, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 1, 2006
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPasesJames E Dunford, Michael J Rogers, Frank H Ebetino, et al.Pageof 7